<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9667671</article-id><article-id pub-id-type="pmc">2150334</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ando</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ying</surname><given-names>D. F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Omuro</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Katsumata</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Narabayashi</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tokue</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fujii</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Igarashi</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wakita</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ohtsu</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Itoh</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Adachi</surname><given-names>I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Taguchi</surname><given-names>T.</given-names></name></contrib></contrib-group><aff>Department of Medicine, National Cancer Center Hospital, Tokyo, Japan.</aff><pub-date pub-type="ppub"><month>6</month><year>1998</year></pub-date><volume>77</volume><issue>11</issue><fpage>1937</fpage><lpage>1943</lpage><abstract><p>To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of 5-fluorouracil (5-FU) in advanced or recurrent breast cancer patients who had been treated previously with at least one chemotherapeutic regimen, patients were treated with docetaxel as a 1-h infusion on day 1 followed by 5-FU as a continuous infusion on days 1 through 5 every 3-4 weeks. Three or six patients were assessed at the following escalating dose levels of docetaxel/5-FU per day: 40/150, 40/300, 50/300, 50/500 and 60/500 mg m(-2). Nineteen patients entered this trial, of whom 18 could be assessed for adverse event and therapeutic efficacy. The DLTs were neutropenia and diarrhoea. The MTDs were 60 mg m(-2) of docetaxel on day 1 and 500 mg m(-2) per day of 5-day continuous infusion of 5-FU. One of 18 patients achieved a complete response and eight achieved partial response (over all response rate: 50%). The recommended doses of docetaxel and 5-day continuous infusion of 5-FU for a phase II trial are 50 mg m(-2) and 500 mg m(-2) per day every 3 or 4 weeks.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00087-0229.tif" xlink:title="scanned-page" xlink:role="1937" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0230.tif" xlink:title="scanned-page" xlink:role="1938" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0231.tif" xlink:title="scanned-page" xlink:role="1939" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0232.tif" xlink:title="scanned-page" xlink:role="1940" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0233.tif" xlink:title="scanned-page" xlink:role="1941" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0234.tif" xlink:title="scanned-page" xlink:role="1942" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0235.tif" xlink:title="scanned-page" xlink:role="1943" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

